These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 33765338)

  • 21. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
    Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
    Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma.
    Wang J; Shi Y; Chen J; Liu J; Zhao X; Pang J; Sun X; Tian Y; Ou Q; Xia F; Chen Y
    Cancer Biol Ther; 2023 Dec; 24(1):2223375. PubMed ID: 37337460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection.
    Jolissaint JS; Soares KC; Seier KP; Kundra R; Gönen M; Shin PJ; Boerner T; Sigel C; Madupuri R; Vakiani E; Cercek A; Harding JJ; Kemeny NE; Connell LC; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Wei AC; Jarnagin WR
    Clin Cancer Res; 2021 Jul; 27(14):4101-4108. PubMed ID: 33963001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
    Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
    Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
    Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
    Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A; Segatto O; Stenzinger A; Saborowski A
    Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity.
    Kamp EJCA; Peppelenbosch MP; Doukas M; Verheij J; Ponsioen CY; van Marion R; Bruno MJ; Groot Koerkamp B; Dinjens WNM; de Vries AC
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00410. PubMed ID: 34608877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
    Nguyen Canh H; Takahashi K; Yamamura M; Li Z; Sato Y; Yoshimura K; Kozaka K; Tanaka M; Nakanuma Y; Harada K
    Histopathology; 2021 Nov; 79(5):731-750. PubMed ID: 34018212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
    Goeppert B; Toth R; Singer S; Albrecht T; Lipka DB; Lutsik P; Brocks D; Baehr M; Muecke O; Assenov Y; Gu L; Endris V; Stenzinger A; Mehrabi A; Schirmacher P; Plass C; Weichenhan D; Roessler S
    Hepatology; 2019 May; 69(5):2091-2106. PubMed ID: 30615206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Profile of Intrahepatic Cholangiocarcinoma.
    Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
    Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.
    Tran Cao HS; Zhang Q; Sada YH; Chai C; Curley SA; Massarweh NN
    Cancer; 2018 Jan; 124(1):74-83. PubMed ID: 28841223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.
    Franssen S; Soares KC; Jolissaint JS; Tsilimigras DI; Buettner S; Alexandrescu S; Marques H; Lamelas J; Aldrighetti L; Gamblin TC; Maithel SK; Pulitano C; Margonis GA; Weiss MJ; Bauer TW; Shen F; Poultsides GA; Marsh JW; Cercek A; Kemeny N; Kingham TP; D'Angelica M; Pawlik TM; Jarnagin WR; Koerkamp BG
    JAMA Surg; 2022 Jul; 157(7):590-596. PubMed ID: 35544131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.